Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BIODESIX INCBDSX · Entity 6053 | CFO, Sec'y & Treasurer | February 20, 2026 | February 24, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BIODESIX INC
Report date February 20, 2026 · Filed February 24, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 16,231 |
Ending reported balance
After 2026-02-23 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-02-20 · Exercise / conversion · Acquired 1,469 · Balance 16,766 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Row 2 · 2026-02-23 · Sale · Disposed 535 · Balance 16,231 F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs. F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 4,406 |
Reported balance
After 2026-02-20 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-02-20 · Exercise / conversion · Disposed 1,469 · Balance 4,406 F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025. F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit (the "RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: These shares of the Issuer's Common Stock were sold automatically to cover taxes upon the vesting of RSUs.
F3: The price reported in Column 4 is a weighted average price of all shares sold on the transaction date by the Issuer's broker to cover taxes upon the vesting of RSUs for certain employees of the Issuer, including the Reporting Person. These shares were sold in multiple transactions at prices ranging from $12.58 to $13.16, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: These numbers have been adjusted to reflect the one-for-twenty reverse stock split effective September 15, 2025.
F5: These RSUs vest in a series of four successive equal annual installments measured from February 20, 2025, generally subject to the Reporting Person's continued service with the Issuer, and have no expiration date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2021 Filed Apr 1, 2021 20:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionStock Options (Right to buy) · Derivative | 13,689 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0000905148-21-000336 · form4.xml · derivative · entry 8 Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,369 Underlying: Common Stock · 13,689 shares Expires 2028-04-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests in 60 successive, equal monthly installments measured from January 1, 2018. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 20:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionStock Options (Right to buy) · Derivative | 14,326 | $0.00 Strike: $0.42 | $0.00 |
DisclosureSEC source: 0000905148-21-000336 · form4.xml · derivative · entry 7 Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,520 Underlying: Common Stock · 14,326 shares Expires 2027-05-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option vests in 60 successive, equal monthly installments measured from January 1, 2017. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 20:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionStock Options (Right to buy) · Derivative | 8,172 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0000905148-21-000336 · form4.xml · derivative · entry 6 Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,172 shares Expires 2026-04-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 20:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionStock Options (Right to buy) · Derivative | 2,526 | $0.00 Strike: $2.62 | $0.00 |
DisclosureSEC source: 0000905148-21-000336 · form4.xml · derivative · entry 5 Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,526 shares Expires 2021-04-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: This option vested 40% on March 28, 2013, and the remaining 60% in 36 successive, equal monthly installments measured from March 28, 2013. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 20:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 13,689 | $0.42 | $5,749.38 |
DisclosureSEC source: 0000905148-21-000336 · form4.xml · nonDerivative · entry 4 Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,713 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 20:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 14,326 | $0.42 | $6,016.92 |
DisclosureSEC source: 0000905148-21-000336 · form4.xml · nonDerivative · entry 3 Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,024 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 20:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 8,172 | $0.84 | $6,864.48 |
DisclosureSEC source: 0000905148-21-000336 · form4.xml · nonDerivative · entry 2 Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 1, 2021 20:51 UTC | BIODESIX INC BDSX · Entity 6053 | Exercise / conversionCommon Stock | 2,526 | $2.62 | $6,618.12 |
DisclosureSEC source: 0000905148-21-000336 · form4.xml · nonDerivative · entry 1 Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,526 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 23, 2021 Filed Mar 14, 2022 21:39 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 5,896 | $0.00 Strike: $0.77 | $0.00 |
DisclosureSEC source: 0001567619-22-006911 · doc1.xml · derivative · entry 1 Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,896 Underlying: Common Stock · 5,896 shares Expires 2029-03-21 F1 · shares: On March 22, 2019, the Reporting Person was granted an option to purchase 17,688 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,896 shares underlying the option. F2 · shares: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 5,896 shares underlying the option. F1 · derivative.exercise_date: On March 22, 2019, the Reporting Person was granted an option to purchase 17,688 shares (as-adjusted for the 0.1684664-for-1 reverse stock split effected on October 19, 2020), the vesting of which was subject to the Issuer's satisfaction of certain performance criteria for each of the 2019, 2020 and 2021 fiscal years. The performance criteria was not met for fiscal year 2019, resulting in the cancellation of 5,896 shares underlying the option. F2 · derivative.exercise_date: On February 23, 2021, the Compensation Committee of the Issuer's board of directors (the "Compensation Committee") confirmed the performance criteria were met for fiscal year 2020, resulting in the vesting of 5,896 shares underlying the option. Read SEC document |
| February 23, 2021 Filed Jul 26, 2023 22:13 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 71,524 | $0.00 Strike: $20.67 | $0.00 |
DisclosureSEC source: 0000905148-23-000510 · form4.xml · derivative · entry 2 Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,524 Underlying: Common Stock · 71,524 shares Expires 2031-02-22 F2 · derivative.exercise_date: This option was fully vested as of the grant date. Read SEC document |
| February 23, 2021 Filed Jul 26, 2023 22:13 UTC | BIODESIX INC BDSX · Entity 6053 | GrantStock Options (Right to buy) · Derivative | 61,439 | $0.00 Strike: $20.67 | $0.00 |
DisclosureSEC source: 0000905148-23-000510 · form4.xml · derivative · entry 1 Cowie Robin Harper · CIK 0001827690 · CFO, Sec'y & Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,439 Underlying: Common Stock · 61,439 shares Expires 2031-02-22 F1 · derivative.exercise_date: This option was scheduled to vest in a series of 60 successive, equal monthly installments measured from February 23, 2021. Read SEC document |
| October 30, 2020 Filed Nov 3, 2020 23:24 UTC | BIODESIX INC BDSX · Entity 6053 | PurchaseCommon Stock | 1,000 | $18.00 | $18,000.00 |
DisclosureSEC source: 0001209191-20-056751 · doc4.xml · nonDerivative · entry 1 Cowie Robin Harper · CIK 0001827690 · CFO, Sec?y & Treasurer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.